Trending...
- Comp-U-Floor ERP to Showcase All-in-One Flooring Software at TISE 2025
- Top Book Printer in Central Ohio announces expansion
- InventHelp Inventor Develops Disposable Covering for Stethoscopes (BDH-357)
HAYWARD, Calif., April 15, 2024 ~ Avirmax Inc. is set to make a significant impact at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore, which will take place from May 7th to 11th, 2024. The company will be presenting two scientific presentations and showcasing their latest progress and data package at exhibitor booth #818.
The ASGCT is the largest international society dedicated to understanding, development, and application of gene and cell therapy. Avirmax's presentations will be focused on their lead candidate ABI-110 for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). The first presentation, titled "Macular retina-targeting AAV capsid identified through multi-species screening in mice, rabbits, pigs, and monkeys," will be given by Li Ou, Ph.D. during the session on AAV Capsid Engineering: Multilevel Approaches for Enhanced AAV Delivery on Friday, May 10th from 3:45pm to 4:00pm.
Dr. Ou's presentation will highlight Avirmax's proprietary novel capsid AAV2.N54, which was developed through capsid engineering. This capsid has shown significantly improved tropism to the macular retina compared to wildtype serotypes and AAV2.7m8 in various animal models including mice, rabbits, pigs, and non-human primates. This promising data has led Avirmax Biopharma to complete cGMP manufacturing of ABI-110 using their VSafTM rAAV Production Platform with Sf-rhabdovirus free Sf9 cells. The company is now preparing for regulatory submission for clinical investigations.
More on Marylandian
The second presentation by Dr. Ou is titled "Comprehensive Head-to-Head Comparisons Demonstrated Key Advantages of The Sf9 System Over HEK293 in rAAV Manufacturing." This will be a poster presentation during the AAV Vectors - Product Development Manufacturing and Approval Considerations session on Friday, May 10th at 12:00pm.
This presentation will focus on the systematic comparison between AAV vectors manufactured by the traditional HEK293 plasmid transfection system and the Sf9/baculoviral infection system. As shown in a publication from Avirmax in Molecular Therapy, the Sf9 system has demonstrated advantages in yields, full capsid ratio, aggregation, purity, and potency over traditional HEK293 systems.
Avirmax's presentations at the ASGCT annual meeting are highly anticipated and could potentially pave the way for new advancements in gene and cell therapy. With their innovative approach to capsid engineering and manufacturing processes, Avirmax is making significant strides towards improving treatments for wet AMD and PCV.
The ASGCT is the largest international society dedicated to understanding, development, and application of gene and cell therapy. Avirmax's presentations will be focused on their lead candidate ABI-110 for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). The first presentation, titled "Macular retina-targeting AAV capsid identified through multi-species screening in mice, rabbits, pigs, and monkeys," will be given by Li Ou, Ph.D. during the session on AAV Capsid Engineering: Multilevel Approaches for Enhanced AAV Delivery on Friday, May 10th from 3:45pm to 4:00pm.
Dr. Ou's presentation will highlight Avirmax's proprietary novel capsid AAV2.N54, which was developed through capsid engineering. This capsid has shown significantly improved tropism to the macular retina compared to wildtype serotypes and AAV2.7m8 in various animal models including mice, rabbits, pigs, and non-human primates. This promising data has led Avirmax Biopharma to complete cGMP manufacturing of ABI-110 using their VSafTM rAAV Production Platform with Sf-rhabdovirus free Sf9 cells. The company is now preparing for regulatory submission for clinical investigations.
More on Marylandian
- King Dumpsters Canton Launches Affordable, Reliable Dumpster Rental Services in Canton, Ohio
- Matthew Cossolotto's The Joy of Public Speaking – Helping Readers Move from Stage Fright to Stage Delight – Wins 2024 Maincrest Media Book Award
- Lady Bird Laser Spa: Empowering Beauty with Advanced Skin Treatments and Exceptional Service
- Profitable Exciting New Entry Into Emerging Global MOBA Digital Game Arena, Plus New Strategic Partnership with The9 Limited: NIP Group; Stock: NIPG
- A Historic Night Awaits: RNHA Celebrating the Power of the Latino Vote at Inauguration 2025
The second presentation by Dr. Ou is titled "Comprehensive Head-to-Head Comparisons Demonstrated Key Advantages of The Sf9 System Over HEK293 in rAAV Manufacturing." This will be a poster presentation during the AAV Vectors - Product Development Manufacturing and Approval Considerations session on Friday, May 10th at 12:00pm.
This presentation will focus on the systematic comparison between AAV vectors manufactured by the traditional HEK293 plasmid transfection system and the Sf9/baculoviral infection system. As shown in a publication from Avirmax in Molecular Therapy, the Sf9 system has demonstrated advantages in yields, full capsid ratio, aggregation, purity, and potency over traditional HEK293 systems.
Avirmax's presentations at the ASGCT annual meeting are highly anticipated and could potentially pave the way for new advancements in gene and cell therapy. With their innovative approach to capsid engineering and manufacturing processes, Avirmax is making significant strides towards improving treatments for wet AMD and PCV.
Filed Under: Business
0 Comments
Latest on Marylandian
- COLORICH PACKAGING Will Participate in the COSME Week 2025 TOKYO and Cosmoprof Worldwide Bologna 2025 Exhibition
- IntellaTriage Launches New Patient Engagement Service
- Momentum Stock Trading: AI-Driven by Tickeron
- Maryland: Preliminary Testing Confirms Highly Pathogenic Avian Influenza in Second Caroline County Farm
- Maryland Young Farmer Advisory Board Meeting Notice
- Maryland: Preliminary Testing Confirms Highly Pathogenic Avian Influenza in Queen Anne's County
- IntellaTriage Launches New Patient Engagement Service
- Cascadia Global Security Launches Cascadia Off-Duty
- Anti-Racism Song from Neal Fox Drops in Time for Martin Luther King Day
- Scaffold Resource Expands Focus on Event Infrastructure Solutions for World-Class Events
- ADS Transform-CV: COTS, Deep Learning-based Computer Vision System for Q/A Application
- Genpak Expands Foodservice Packaging to Include Durable, Polypropylene Bowls
- Andreozzi + Foote Files Lawsuits Alleging Sexual Abuse Against Ed Waters Track and Field Alliance Club of Baltimore
- Cynthia Cephas Photography Launches 2025 New Year Headshot Promotion
- DayPass Expands to 50 New Destinations in 2024, Bringing Luxury Day Experiences to Travelers and Locals
- Dr. Lauren Anderson Led a Successful CE Event: Digital Planning and Execution
- Scythian Returns to the Weinberg Center with High-Energy Roots Music
- "One World in a New World" Amplifies Voices of Transformation, Resilience, and Global Connection
- WalkerHughes Insurance Expands Footprint With Acquisition of Independent Brokers Agency LLC
- Hawk Tuah VIP Shop launches Exclusive Merchandise line for Viral Meme Fans